Journal article
A New Era for Antiplatelet Therapy in Patients With Acute Coronary Syndrome
The American journal of the medical sciences, Vol.340(5), pp.407-411
11/01/2010
DOI: 10.1097/MAJ.0b013e3181ee5bfb
PMID: 20818228
Abstract
Platelet aggregation is one of the most important underlying mechanisms in acute coronary syndromes (ACS). Antiplatelet therapy is considered as a cornerstone therapy and is widely used in these patients. Clopidogrel is currently a class I indication in patients with ACS. However, different degrees of resistance to clopidogrel have been the subject of many recent studies that led to higher dosing regimens of clopidogrel. Failure of clopidogrel to provide consistent platelet aggregation inhibition in all patients made the emergence of new more reliable agents crucial. Prasugrel and ticagrelor are the 2 new antiplatelet agents that have recently been compared with clopidogrel in patients with ACS. This article reviews the current evidence that supports the use of each of those agents and provides clinicians with an objective summary supporting their use.
Details
- Title: Subtitle
- A New Era for Antiplatelet Therapy in Patients With Acute Coronary Syndrome
- Creators
- Chadi Dib - University of Oklahoma Health Sciences CenterElias B. Hanna - University of Oklahoma Health Sciences CenterMazen S. Abu-Fadel - University of Oklahoma Health Sciences Center
- Resource Type
- Journal article
- Publication Details
- The American journal of the medical sciences, Vol.340(5), pp.407-411
- Publisher
- Elsevier
- DOI
- 10.1097/MAJ.0b013e3181ee5bfb
- PMID
- 20818228
- ISSN
- 0002-9629
- eISSN
- 1538-2990
- Number of pages
- 5
- Language
- English
- Date published
- 11/01/2010
- Academic Unit
- Cardiovascular Medicine; Internal Medicine
- Record Identifier
- 9984359565402771
Metrics
18 Record Views